Vor Biopharma Inc.
HealthcareNASDAQ:VOR · NASDAQ Global Select
+$0.27 today
Vol 0.54M · Avg 1.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
423.6%
avg -1.8%
ROIC
-84.6%
avg -47.7%
ROA
-150.0%
avg -115.9%
Analysis
ROE is currently the strongest return metric at 423.6% versus its period average of -1.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Ang MBBS | Strategic Advisor | $2.00M | — | 51 | $911,318.00 | 13.30% |
Jean-Paul Kress | Chairman, President & CEO | $1.01M | — | 61 | $4.16M | 60.77% |
Jeremy Sokolove | Chief Medical Officer | $695,160.00 | — | 52 | $27,900.00 | 0.41% |
Sandesh Mahatme | Chief Business Officer & Chief Financial Officer | $603,814.00 | — | 61 | $1.39M | 20.26% |
Siddhartha Mukherjee DPHIL | Scientific Founder & Chairman of Scientific Advisory Board | — | — | 55 | — | — |
Carol Lincoln | Head of Human Resources | — | — | — | — | — |
Navid Z. Khan | Chief Medical Affairs Officer | — | — | — | — | — |
Adi Osovsky | General Counsel | — | — | — | — | — |
Dallan Murray | Chief Commercial Officer | — | — | 56 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
85
$110.81M
Net Sentiment
$110.81M
Net selling
Most Active
RA CAPITAL MANAGEMENT, L.P.
43 transactions
1–10 of 85
Analysis
Insiders reported 0 buys worth $0.00 and 85 sells worth $110.81M over the last 12 months. That adds up to net selling of $110.81M. RA CAPITAL MANAGEMENT, L.P. was the most active insider with 43 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Forte Biosciences, Inc.
NASDAQ:FBRX
$243.83M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Anixa Biosciences, Inc.
NASDAQ:ANIX
$84.04M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Actuate Therapeutics Inc
ACTU
$48.33M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages VOR?
Vor Biopharma Inc. (VOR) lists 9 active executives. The top listed executive is Jeremy Sokolove, Chief Medical Officer.
Are VOR insiders buying or selling?
Recent insider activity shows net buying of $7.19M.
Explore More
Continue the stock analysis
Jump to another research area for this company.